Clinical trials: Asthmatic Patients
Asthma
4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
This 4-week clinical study evaluates the efficacy and safety of Albuterol Sulfate HFA Inhalation Aerosol in comparison with the Active Control, Proventil-HFA (3M Pharmaceuticals, Inc) in pediatric patients (4-11 years old) with…
- Trial name
- NCT00634517
- Testing
- Armstrong Albuterol Sulfate Inhalation Aerosol, Albuterol Sulfate Inhalation Aerosol
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)
A study to assess the clinical effect of montelukast sodium with concomitant administration of inhaled budesonide in asthmatic patients.
- Trial name
- NCT00140946
- Testing
- MK0476; montelukast sodium/Duration of Treatment: 16 weeks
- Volunteers
- 546 people
- Sponsor
- Organon and Co
Asthma
Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)
This trial will compare the effectiveness of one dose of ciclesonide against one dose of budesonide in patients with asthma. The aim of the present trial is to compare the efficacy of ciclesonide versus budesonide on pulmonary…
- Trial name
- NCT00163384
- Testing
- Ciclesonide
- Where
- 19 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Asthma, Moderate Asthma
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.
- Trial name
- NCT02999711
- Testing
- REGN3500
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients
The primary objective will be to compare the impact of the study formulations on pulmonary function in persistent asthma carriers.
- Trial name
- NCT01202084
- Testing
- Formoterol/Fluticasone, Foraseq®, Fluticasone
- Where
- Brazil
- Volunteers
- 222 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment…
- Trial name
- NCT01867125
- Testing
- Lebrikizumab
- Where
- 181 sites in United States, Argentina and 24 more
- Volunteers
- 1,081 people
- Sponsor
- Hoffmann-La Roche
Asthma
Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base
This randomized, single-dose, double-blind, double-dummy, four-period, four-sequence, four-treatment, placebo and active controlled, comparative, multiple-center, crossover-design bronchoprovocation study has been designed to…
- Trial name
- NCT03549897
- Testing
- 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Amneal Ireland Limited
Asthma
A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma
Asthma is a common, chronic inflammatory disease of the bronchial airways, with a reported prevalence in most industrialized countries of between 5 to 10 % of the adult population.
- Trial name
- NCT01436890
- Testing
- Revamilast
- Where
- 42 sites in Czechia, India and 3 more
- Volunteers
- 273 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Asthma
CARE FOR ALL：an Evaluation of an Asthma QIP
This is an evaluation on an asthma Quality Improvement Program (QIP, including GINA guideline education/training and implementation) to understand the change of physician behaviours, which leads to the change of patient outcomes.
- Trial name
- CARE FOR ALL (NCT05440097)
- Testing
- QIP intervention
- Where
- 32 sites in China
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- MM09-SIT-063 (NCT07904052)
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Asthma
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic…
- Trial name
- NCT00452348
- Testing
- Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
- Where
- 81 sites in United States, Argentina and 3 more
- Volunteers
- 628 people
- Sponsor
- GlaxoSmithKline
Severe Asthma
Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia
ELBRUS is a 12-month (52-week), multi-centre, prospective, non-comparative and non-interventional (observational), post-reimbursement real-world evidence study that will assess patient-reported outcomes after tezepelumab…
- Trial name
- ELBRUS (NCT06566885)
- Where
- 15 sites in Russia
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Asthma
Linear Growth Study (0476-097)(COMPLETED)
The purpose of this study is to compare the effect of montelukast with placebo and beclomethasone on the average rate of linear growth over a period of 56 weeks in children with mild asthma.
- Trial name
- NCT00395408
- Testing
- MK0476, montelukast sodium / Duration of Treatment : 56 Weeks, Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks
- Volunteers
- 360 people
- Sponsor
- Organon and Co
Allergy
A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites
A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.
- Trial name
- NCT00660452
- Testing
- Staloral
- Where
- China
- Volunteers
- 484 people
- Sponsor
- Stallergenes Greer
Asthma
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of…
- Trial name
- NCT06419413
- Where
- 21 sites in China
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent…
- Trial name
- NCT03226392
- Testing
- QAW039
- Where
- 142 sites in United States, Brazil and 16 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use…
- Trial name
- Epi-Asthma (NCT05169619)
- Where
- 37 sites in Portugal
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898
In this integrated, multi-part, Phase I study, the safety, tolerability, food effect, pharmacokinetic (PK) and pharmacodynamic (PD) properties of single and repeated doses of AZD9898 will be investigated.
- Trial name
- NCT03140072
- Testing
- AZD9898
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg
This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate…
- Trial name
- NCT00350207
- Testing
- Tiotropium bromide, Salmeterol xinafoate
- Where
- 109 sites in Austria, Belgium and 12 more
- Volunteers
- 388 people
- Sponsor
- Boehringer Ingelheim
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim